Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neuromyelitis Optica × LFB-R603 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Follicular 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Optic Neuritis 1 Neuromyelitis Optica 1 Myelitis, Transverse 1 Lymphoma, Mantle-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

ublituximab 1 Rituximab 1 LFB-R603 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed

6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡